These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 27021055)

  • 1. Is the evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder flawed?
    Hoekstra PJ; Buitelaar JK
    Eur Child Adolesc Psychiatry; 2016 Apr; 25(4):339-40. PubMed ID: 27021055
    [No Abstract]   [Full Text] [Related]  

  • 2. Methylphenidate for attention-deficit/hyperactivity disorder: The longest debate.
    Levy F
    Aust N Z J Psychiatry; 2016 Jul; 50(7):616-7. PubMed ID: 27066820
    [No Abstract]   [Full Text] [Related]  

  • 3. The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Storebø OJ; Faltinsen E; Zwi M; Simonsen E; Gluud C
    Clin Pharmacol Ther; 2018 Oct; 104(4):606-609. PubMed ID: 30006934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730
    [No Abstract]   [Full Text] [Related]  

  • 5. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Zarinara AR; Mohammadi MR; Hazrati N; Tabrizi M; Rezazadeh SA; Rezaie F; Akhondzadeh S
    Hum Psychopharmacol; 2010 Nov; 25(7-8):530-5. PubMed ID: 20860068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual fields in children with attention-deficit/hyperactivity disorder before and after treatment with stimulants.
    Ghanizadeh A
    Acta Ophthalmol; 2010 Mar; 88(2):e56. PubMed ID: 19508459
    [No Abstract]   [Full Text] [Related]  

  • 7. Methylphenidate (Ritalin) use and abuse.
    Crutchley A; Temlett JA
    S Afr Med J; 1999 Oct; 89(10):1076-9. PubMed ID: 10582063
    [No Abstract]   [Full Text] [Related]  

  • 8. Question 2 Should a child with ADHD and epilepsy be given ritalin?
    Boyes C
    Arch Dis Child; 2010 Sep; 95(9):759-61. PubMed ID: 20716679
    [No Abstract]   [Full Text] [Related]  

  • 9. Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children: A viewpoint by Raul R. Silva.
    Silva RR
    Drugs; 2006; 66(8):1127-8; discussion 1128. PubMed ID: 16789798
    [No Abstract]   [Full Text] [Related]  

  • 10. Responses to methylphenidate in Attention-Deficit/Hyperactivity Disorder and normal children: update 2002.
    Rapoport JL; Inoff-Germain G
    J Atten Disord; 2002; 6 Suppl 1():S57-60. PubMed ID: 12685519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase in Menstrual Cycle Length Induced by Extended-Release Methylphenidate in an Adolescent with Attention-Deficit/Hyperactivity Disorder.
    Mutlu C; Bahalı K; Gunes H; Adaletli H
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):860-861. PubMed ID: 26397126
    [No Abstract]   [Full Text] [Related]  

  • 12. [Methylphenidate. A drug for attention deficit disorders to be used with precaution].
    Taéron C
    Rev Infirm; 2009 Jun; (151):47-9. PubMed ID: 19579855
    [No Abstract]   [Full Text] [Related]  

  • 13. Drugs and children.
    Pinkham JR
    ASDC J Dent Child; 2002; 69(1):10. PubMed ID: 12119805
    [No Abstract]   [Full Text] [Related]  

  • 14. WITHDRAWN: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2016 May; (5):CD005041. PubMed ID: 27228176
    [No Abstract]   [Full Text] [Related]  

  • 15. Trichotillomania in Attention-Deficit/Hyperactivity Disorder Under Methylphenidate Treatment.
    Kara T; Akaltun İ
    J Clin Psychopharmacol; 2017 Aug; 37(4):484. PubMed ID: 28492426
    [No Abstract]   [Full Text] [Related]  

  • 16. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
    Janols LO; Liliemark J; Klintberg K; von Knorring AL
    Nord J Psychiatry; 2009 Nov; 63(6):508-16. PubMed ID: 19958258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylphenidate euphoria.
    Corrigall R; Ford T
    J Am Acad Child Adolesc Psychiatry; 1996 Nov; 35(11):1421. PubMed ID: 8936903
    [No Abstract]   [Full Text] [Related]  

  • 18. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
    McGough JJ; McBurnett K; Bukstein O; Wilens TE; Greenhill L; Lerner M; Stein M
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):351-6. PubMed ID: 16768642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder.
    Lurie S; O'Quinn A
    J Neuropsychiatry Clin Neurosci; 1991; 3(1):41-50. PubMed ID: 7580171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The answerable question and a hierarchy of evidence.
    Hamilton J
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):596-600. PubMed ID: 15908843
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.